Do analysts recommend KYNB or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer KYNB or XBIO?

In the previous week, Kyntra Bio and Kyntra Bio both had 1 articles in the media. Kyntra Bio's average media sentiment score of 0.93 beat Xenetic Biosciences' score of 0.63 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XBIO or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 324.33%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate AIMD or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIMD or XBIO more profitable?

Xenetic Biosciences has a net margin of -70.03% compared to Ainos' net margin of -11,912.10%. Xenetic Biosciences' return on equity of -39.28% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Xenetic Biosciences -70.03% -39.28% -33.47%

Does the media prefer AIMD or XBIO?

In the previous week, Ainos had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.63 beat Ainos' score of 0.62 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QNTM or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer QNTM or XBIO?

In the previous week, Quantum Biopharma had 5 more articles in the media than Xenetic Biosciences. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.45 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xenetic Biosciences (XBIO) Competitors

$3.24 -0.19 (-5.51%)

As of 11:38 AM Eastern

Compare

XBIO vs. BRNS, KYNB, DYAI, AIMD, and QNTM

Should you buy Xenetic Biosciences stock or one of its competitors? MarketBeat compares Xenetic Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenetic Biosciences include Barinthus Biotherapeutics (BRNS), Kyntra Bio (KYNB), Dyadic International (DYAI), Ainos (AIMD), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Xenetic Biosciences had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Xenetic Biosciences and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.87 beat Xenetic Biosciences' score of 0.63 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Xenetic Biosciences	Positive

Barinthus Biotherapeutics has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 512.56%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has lower revenue, but higher earnings than Barinthus Biotherapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.78	-$66.43M	-$1.29	N/A
Xenetic Biosciences	$3.19M	2.33	-$2.68M	-$1.20	N/A

Summary

Barinthus Biotherapeutics beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kyntra Bio has higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.37	$183.45M	$40.46	0.17
Xenetic Biosciences	$3.19M	2.33	-$2.68M	-$1.20	N/A

Kyntra Bio has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Xenetic Biosciences' net margin of -70.03%. Kyntra Bio's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

In the previous week, Kyntra Bio and Kyntra Bio both had 1 articles in the media. Kyntra Bio's average media sentiment score of 0.93 beat Xenetic Biosciences' score of 0.63 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kyntra Bio beats Xenetic Biosciences on 11 of the 14 factors compared between the two stocks.

How does Xenetic Biosciences compare to Dyadic International?

Xenetic Biosciences (NASDAQ:XBIO) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 324.33%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xenetic Biosciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

In the previous week, Xenetic Biosciences had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Xenetic Biosciences and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.94 beat Xenetic Biosciences' score of 0.63 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenetic Biosciences	Positive
Dyadic International	Positive

Xenetic Biosciences has a net margin of -70.03% compared to Dyadic International's net margin of -192.40%. Xenetic Biosciences' return on equity of -39.28% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Xenetic Biosciences has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.19M	2.33	-$2.68M	-$1.20	N/A
Dyadic International	$3.09M	8.34	-$7.36M	-$0.23	N/A

Summary

Xenetic Biosciences and Dyadic International tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Ainos?

Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has higher revenue and earnings than Ainos. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$18.11K	950.72	-$14.77M	-$2.89	N/A
Xenetic Biosciences	$3.19M	2.33	-$2.68M	-$1.20	N/A

In the previous week, Ainos had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.63 beat Ainos' score of 0.62 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenetic Biosciences has a net margin of -70.03% compared to Ainos' net margin of -11,912.10%. Xenetic Biosciences' return on equity of -39.28% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

Ainos has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

15.1% of Xenetic Biosciences shares are owned by institutional investors. 9.8% of Ainos shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Xenetic Biosciences beats Ainos on 8 of the 13 factors compared between the two stocks.

How does Xenetic Biosciences compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Quantum Biopharma had 5 more articles in the media than Xenetic Biosciences. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.45 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenetic Biosciences has higher revenue and earnings than Quantum Biopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Xenetic Biosciences	$3.19M	2.33	-$2.68M	-$1.20	N/A

Quantum Biopharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quantum Biopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Xenetic Biosciences beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.47M	$2.96B	$6.50B	$12.22B
Dividend Yield	N/A	1.69%	2.69%	5.31%
P/E Ratio	-2.72	18.14	23.86	24.04
Price / Sales	2.33	303.89	495.07	91.24
Price / Cash	N/A	55.54	41.39	55.53
Price / Book	1.00	3.91	9.94	6.56
Net Income	-$2.68M	$75.85M	$3.56B	$337.00M
7 Day Performance	2.92%	-2.92%	-1.93%	-1.45%
1 Month Performance	4.89%	-3.85%	1.27%	2.18%
1 Year Performance	5.06%	21.75%	27.45%	31.54%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	0.6632 of 5 stars	$3.24 -5.5%	N/A	+8.2%	$7.47M	$3.19M	N/A	4	News Coverage Gap Down
BRNS Barinthus Biotherapeutics	2.4281 of 5 stars	$0.70 +2.7%	$4.00 +471.6%	-32.8%	$27.84M	$14.97M	N/A	107	Positive News Short Interest Increase Gap Down
KYNB Kyntra Bio	0.9199 of 5 stars	$7.01 +2.3%	N/A	N/A	$27.73M	$6.44M	N/A	570
DYAI Dyadic International	2.0229 of 5 stars	$0.76 +0.6%	$3.00 +294.8%	-25.4%	$27.51M	$3.09M	N/A	7	Gap Down
AIMD Ainos	0.5085 of 5 stars	$2.56 -19.0%	N/A	-31.4%	$26.94M	$120K	N/A	40	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. BRNS, KYNB, DYAI, AIMD, and QNTM

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Summary

How does Xenetic Biosciences compare to Kyntra Bio?

Summary

How does Xenetic Biosciences compare to Dyadic International?

Summary

How does Xenetic Biosciences compare to Ainos?

Summary

How does Xenetic Biosciences compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. BRNS, KYNB, DYAI, AIMD, and QNTM

How does Xenetic Biosciences compare to Barinthus Biotherapeutics?

Is BRNS or XBIO more profitable?

Do institutionals and insiders hold more shares of BRNS or XBIO?

Does the media prefer BRNS or XBIO?

Which has more volatility & risk, BRNS or XBIO?

Do analysts prefer BRNS or XBIO?

Which has better earnings & valuation, BRNS or XBIO?

Summary

How does Xenetic Biosciences compare to Kyntra Bio?

Do analysts recommend KYNB or XBIO?

Which has preferable valuation & earnings, KYNB or XBIO?

Which has more risk & volatility, KYNB or XBIO?

Is KYNB or XBIO more profitable?

Does the media prefer KYNB or XBIO?

Do insiders and institutionals hold more shares of KYNB or XBIO?

Summary

How does Xenetic Biosciences compare to Dyadic International?

Do analysts recommend XBIO or DYAI?

Do insiders & institutionals hold more shares of XBIO or DYAI?

Which has more volatility & risk, XBIO or DYAI?

Does the media refer more to XBIO or DYAI?

Is XBIO or DYAI more profitable?

Which has preferable earnings and valuation, XBIO or DYAI?

Summary

How does Xenetic Biosciences compare to Ainos?

Do analysts rate AIMD or XBIO?

Which has better valuation & earnings, AIMD or XBIO?

Does the media prefer AIMD or XBIO?

Is AIMD or XBIO more profitable?

Which has more volatility & risk, AIMD or XBIO?

Do institutionals and insiders hold more shares of AIMD or XBIO?

Summary

How does Xenetic Biosciences compare to Quantum Biopharma?

Does the media prefer QNTM or XBIO?

Which has better valuation & earnings, QNTM or XBIO?

Is QNTM or XBIO more profitable?

Do institutionals and insiders hold more shares of QNTM or XBIO?

Which has more volatility & risk, QNTM or XBIO?

Do analysts rate QNTM or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools